Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Gastroenterol Hepatol ; 12(12): 2085-91.e1, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24815326

ABSTRACT

BACKGROUND & AIMS: We investigated the effects of the fatty acid-bile acid conjugate 3ß-arachidyl-amido, 7α-12α-dihydroxy, 5ß-cholan-24-oic acid (Aramchol; Trima Israel Pharmaceutical Products Ltd, Maabarot, Israel) in a phase 2 trial of patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n = 20/group). The main end point was the difference between groups in the change in liver fat content according to magnetic resonance spectroscopy. The secondary end points focused on the differences between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function. RESULTS: No serious or drug-related adverse events were observed in the 58 patients who completed the study. Over 3 months, liver fat content decreased by 12.57% ± 22.14% in patients given 300 mg/day Aramchol, but increased by 6.39% ± 36.27% in the placebo group (P = .02 for the difference between groups, adjusted for age, sex, and body mass index). Liver fat content decreased in the 100-mg Aramchol group, by 2.89% ± 28.22%, but this change was nonsignificant (P = .35), indicating a dose-response relationship (P for trend = .01). Groups given Aramchol had nonsignificant improvements over time in endothelial function and levels of alanine aminotransferase and adiponectin, but homeostasis model assessment scores did not change. The appropriateness of a single daily dose was confirmed by pharmacokinetic analysis. CONCLUSIONS: Three months' administration of the fatty acid-bile acid conjugate Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. ClinicalTrials.gov number: NCT01094158.


Subject(s)
Cholic Acids/therapeutic use , Fats/analysis , Gastrointestinal Agents/therapeutic use , Liver/pathology , Non-alcoholic Fatty Liver Disease/drug therapy , Adolescent , Adult , Aged , Biopsy , Cholic Acids/adverse effects , Double-Blind Method , Female , Gastrointestinal Agents/adverse effects , Humans , Israel , Magnetic Resonance Spectroscopy , Male , Middle Aged , Placenta , Pregnancy , Treatment Outcome , Young Adult
2.
Arch Med Res ; 41(6): 397-404, 2010 Aug.
Article in English | MEDLINE | ID: mdl-21044742

ABSTRACT

BACKGROUND AND AIMS: Suppression of stearoyl-coenzyme A desaturase (SCD) activity leads to reduction of obesity, fatty liver as well as of insulin resistance. It was, however, recently reported to enhance atherogenesis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atherogenesis and how. METHODS: Aramchol was tested in vitro in cultured cells and in vivo in rodents. RESULTS: Aramchol, at very low concentrations, reduced SCD activity in liver microsomes of mice. Aramchol enhanced cholesterol efflux from macrophages more than twofold. In vivo it increased fecal sterol output and decreased markedly plasma cholesterol levels in mice. In ApoE(-/-), LDRL(-/-) and C57Bl6 mice, the effects of Aramchol on atherogenesis were non-atherogenic. CONCLUSIONS: Aramchol reduces SCD activity and is non-atherogenic. It may offer a means to obtain the desirable hepatic metabolic effects of SCD inhibition without the deleterious atherogenic effect.


Subject(s)
Atherosclerosis/etiology , Cholic Acids/pharmacology , Liver/drug effects , Liver/enzymology , Stearoyl-CoA Desaturase/antagonists & inhibitors , Animals , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Cholesterol/metabolism , Cricetinae , Diet, Atherogenic , Enzyme Inhibitors/pharmacology , Female , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/metabolism , Male , Mesocricetus , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, LDL/deficiency , Receptors, LDL/genetics
3.
Eur J Gastroenterol Hepatol ; 20(12): 1205-13, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18989145

ABSTRACT

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries. It has no accepted medical therapy. Fatty acid-bile acid conjugates (FABACs) were proven to prevent diet-induced NAFLD in rodents. AIM: This study was undertaken to test whether oral FABACs are also effective in reducing liver fat in preestablished diet-induced NAFLD. METHODS: NAFLD was induced in mice and rats by a high-fat diet and maintained by various proportions thereof. The FABACs used were conjugates of cholic acid with either arachidic or stearic acids. RESULTS: FABAC therapy reduced liver fat in all four series of experiments. The rapidity of the effect was inversely proportional to the concentration of fat in the maintenance diet. In mice on a 25% maintenance diet FABACs decreased total liver lipids by about 30% in 4 weeks (P<0.03). Diglycerides (P<0.003) and triglycerides (P<0.01) were the main neutral liver lipids that decreased during FABAC therapy. Both FABACs tested reduced liver fat in NAFLD at doses of 25 and 150 mg/kg/day. High-fat diet increased, whereas FABAC therapy decreased plasma 16 : 1/(16 : 0+16 : 1) fatty acid ratio - a marker of stearoyl CoA desaturase activity. In HepG2 cells FABACs decreased de-novo fatty acid synthesis dose dependently. CONCLUSION: Oral FABAC therapy decreased liver fat in preestablished NAFLD in mice and rats. Inhibition of stearoyl CoA desaturase activity and fatty acid synthesis are mechanisms that may contribute to this decrease. FABACs may be potential therapeutic agents for human NAFLD.


Subject(s)
Bile Acids and Salts/therapeutic use , Dietary Fats/adverse effects , Fatty Acids/therapeutic use , Fatty Liver/drug therapy , Animals , Blood Glucose/metabolism , Cholic Acids/therapeutic use , Dietary Fats/administration & dosage , Disease Models, Animal , Drug Evaluation, Preclinical , Fatty Acids/biosynthesis , Fatty Liver/etiology , Fatty Liver/metabolism , Fatty Liver/pathology , Lipid Metabolism , Liver/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Rats , Rats, Inbred F344 , Stearoyl-CoA Desaturase/blood , Weight Gain
4.
Arch Biochem Biophys ; 471(1): 63-71, 2008 Mar 01.
Article in English | MEDLINE | ID: mdl-18167305

ABSTRACT

Fatty acid bile acid conjugates (FABACs) prevent and dissolve cholesterol gallstones and prevent diet induced fatty liver, in mice. The present studies aimed to test their hypocholesterolemic effects in mice. Gallstone susceptible (C57L/J) mice, on high fat (HFD) or regular diet (RD), were treated with the conjugate of cholic acid with arachidic acid (FABAC; Aramchol). FABAC reduced the elevated plasma cholesterol levels induced by the HFD. In C57L/J mice, FABAC reduced plasma cholesterol by 50% (p<0.001). In mice fed HFD, hepatic cholesterol synthesis was reduced, whereas CYP7A1 activity and expression were increased by FABAC. The ratio of fecal bile acids/neutral sterols was increased, as was the total fecal sterol excretion. In conclusion, FABACs markedly reduce elevated plasma cholesterol in mice by reducing the hepatic synthesis of cholesterol, in conjunction with an increase of its catabolism and excretion from the body.


Subject(s)
Anticholesteremic Agents/administration & dosage , Anticholesteremic Agents/chemistry , Bile Acids and Salts/administration & dosage , Cholic Acids/administration & dosage , Animals , Anticholesteremic Agents/therapeutic use , Bile Acids and Salts/therapeutic use , Body Weight/drug effects , Body Weight/genetics , Cholesterol/analysis , Cholesterol/blood , Cholic Acids/therapeutic use , Dietary Fats/administration & dosage , Eicosanoic Acids/administration & dosage , Feces/chemistry , Gallstones/enzymology , Gallstones/genetics , Gallstones/physiopathology , Gallstones/prevention & control , Genetic Predisposition to Disease , Lipoproteins/blood , Mice , Mice, Inbred C57BL , Microsomes, Liver/chemistry , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Organ Size/drug effects , Organ Size/genetics , Triglycerides/blood
5.
Biochem J ; 396(3): 529-36, 2006 Jun 15.
Article in English | MEDLINE | ID: mdl-16522192

ABSTRACT

FABACs (fatty acid-bile acid conjugates) are synthetic molecules that are designed to treat a range of lipid disorders. The compounds prevent cholesterol gallstone formation and diet-induced fatty liver, and increase reverse cholesterol transport in rodents. The aim of the present study was to investigate the effect of FABACs on cholesterol efflux in human cells. Aramchol (3beta-arachidylamido-7alpha,12alpha,5beta-cholan-24-oic acid) increased cholesterol efflux from human skin fibroblasts in a dose-dependent manner in the absence of known efflux mediators such as apoA-I (apolipoprotein A-I), but had little effect on phospholipid efflux. An LXR (liver X receptor) agonist strongly increased Aramchol-induced cholesterol efflux; however, in ABCA1 (ATP-binding cassette transporter A1)-deficient cells from Tangier disease patients, the Aramchol effect was absent, indicating that activity of ABCA1 was required. Aramchol did not affect ABCA1 expression, but plasma membrane levels of the transporter increased 2-fold. Aramchol is the first small molecule that induces ABCA1-dependent cholesterol efflux without affecting transcriptional control. These findings may explain the beneficial effect of the compound on atherosclerosis.


Subject(s)
ATP-Binding Cassette Transporters/physiology , Apolipoprotein A-I/physiology , Bile Acids and Salts/pharmacology , Cholesterol/metabolism , Fibroblasts/physiology , ATP Binding Cassette Transporter 1 , Arachidonic Acid/pharmacology , Cell Membrane/drug effects , Cell Membrane/metabolism , Centrifugation, Density Gradient , Cholic Acids , DNA-Binding Proteins/agonists , Fatty Acids/pharmacology , Fibroblasts/drug effects , Humans , Hydrocarbons, Fluorinated , Liver X Receptors , Orphan Nuclear Receptors , Phospholipids/metabolism , Receptors, Cytoplasmic and Nuclear/agonists , Stimulation, Chemical , Sulfonamides/pharmacology , Tangier Disease/physiopathology
6.
Article in English | MEDLINE | ID: mdl-16089349

ABSTRACT

Fatty acid bile acid conjugates (FABACs) are novel synthetic lipid molecules, which were designed for the treatment of cholesterol gallstones. The rationale was to combine a cholesterol solubilizing moiety (a saturated fatty acid) with a bile acid (cholic acid) as a vehicle to enable secretion into bile and entry into the enterohepatic circulation. An amide bond was used to provide stability against intestinal degradation. Initial in vitro studies showed that FABACs are indeed cholesterol solubilizers, able to prevent biliary cholesterol crystallization. Arachidyl-amido-cholanoic acid (Aramchol) was found to be the most potent FABAC in these studies. Animal studies revealed that Aramchol was absorbed after oral administration and could prevent cholesterol crystallization as well as dissolve preformed crystals in rodents fed a lithogenic diet. In gallstone susceptible mice, Aramchol prevented gallstone formation and dissolved gallstones. FABACs were found to be metabolically active substances, also able to decrease blood cholesterol, atherosclerotic plaques and fat accumulation in the liver in several animal species. The underlying mechanisms of action are under active investigation, and several effects, e.g. on cholesterol and bile salt metabolizing enzymes as well as cholesterol efflux from cells have been discovered. These findings are, however, only the beginning of our understanding of the metabolic actions as well as the potential of use of FABACs as therapeutic agents.


Subject(s)
Bile Acids and Salts/therapeutic use , Fatty Acids/therapeutic use , Gallstones/drug therapy , Animals , Arteriosclerosis/prevention & control , Bile/drug effects , Cholesterol/metabolism , Fatty Liver/metabolism , Gallstones/prevention & control , Humans
7.
Eur J Gastroenterol Hepatol ; 15(6): 649-55, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12840677

ABSTRACT

BACKGROUND: Fatty acid bile acid conjugates (FABACs) are novel synthetic molecules that solubilize cholesterol, prevent cholesterol crystal and gallstone formation, and dissolve pre-existing gallstones in mice. They are thus potential agents for gallstone prevention and treatment. The available knowledge concerning their biliary, systemic or possible toxic effects is, however, incomplete. AIM: To obtain information regarding biliary and systemic effects of FABACs. METHODS: Hamsters, rats and mice were administered C20-FABAC intragastrically, and serum and bile chemistries, organ histology, animal wellbeing, and survival were monitored. RESULTS: FABAC feeding (150 mg/kg/day) caused no adverse effects in any of the animal species studied. FABAC did not influence biliary cholesterol, phospholipid, or bile-salt concentrations in mice. In hamsters, biliary cholesterol concentration decreased slightly, but effects on phospholipids and bile salts were inconsistent. In some mouse strains, FABAC supplementation increased transaminases slightly. In hamsters and rats, transaminases were mainly unaffected or even decreased. Serum alkaline phosphatase, creatinine, albumin and glucose were generally unaffected by FABAC feeding. No gross or histopathological differences between controls and FABAC-fed animals were noted in any of the organs investigated. CONCLUSIONS: C20-FABAC given at a pharmacological dose is safe and devoid of any significant toxic effects in three different animal species.


Subject(s)
Bile/drug effects , Cholic Acid/toxicity , Fatty Acids/toxicity , Animals , Bile/metabolism , Blood Glucose/drug effects , Cholesterol/metabolism , Creatinine/blood , Cricetinae , Drug Evaluation, Preclinical , Lipid Metabolism , Liver/drug effects , Liver/enzymology , Male , Mesocricetus , Mice , Mice, Inbred C57BL , Rats , Rats, Wistar , Serum Albumin/drug effects , Species Specificity
8.
Hepatology ; 38(2): 436-42, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12883488

ABSTRACT

Fatty acid bile acid conjugates (FABACs) are a new family of synthetic molecules designed to solubilize biliary cholesterol. They were shown to prevent and dissolve cholesterol gallstones in inbred C57L/J mice fed a lithogenic, high-fat diet (HFD). In these mice, fatty liver was observed in the controls but not in the FABAC-treated ones. The present study was designed to study the effect of FABAC (arachidyl-amido-cholanoic acid) on diet-induced fatty liver in rats, hamsters, and mice. The fatty liver score (on a scale of 0-4 by light microscopy) was 4.0 in control hamsters and 0.3 in the FABAC-fed hamsters (P <.001). In mice it was 1.5 and 0.4, respectively (P <.01). The lipid/protein ratio in the liver was 1.3 +/- 0.44 (mg lipid/mg protein) in control rats and 0.66 +/- 0.04 in the FABAC group (P =.001) after 14 days. In hamsters it was 1.41 +/- 0.27 and 1.11 +/- 0.20, respectively (P =.03), after 21 days. In Imperial Charles River (ICR) mice the ratio was 0.34 +/- 0.10 and 0.17 +/- 0.07 (P =.03), respectively, after 24 days. Liver fat concentration, measured as mg lipid/g liver tissue, decreased similarly by FABAC feeding. The decrease in liver fat affected mainly the triglyceride levels. FABAC-fed animals gained weight similarly to the controls. Triglyceride absorption was unaffected by FABAC supplementation. In conclusion, oral FABAC therapy prevents/reduces the development of fatty liver in animals consuming a HFD.


Subject(s)
Bile Acids and Salts/pharmacology , Fatty Liver/drug therapy , Fatty Liver/prevention & control , Administration, Oral , Animals , Body Weight , Cholic Acids , Cricetinae , Dietary Fats/pharmacokinetics , Fatty Liver/pathology , Female , Liver/metabolism , Liver/pathology , Male , Mesocricetus , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Mice, Mutant Strains , Rats , Rats, Wistar , Triglycerides/pharmacokinetics , Triolein/pharmacokinetics , Tritium
9.
Hepatology ; 35(3): 597-600, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11870372

ABSTRACT

Gallstones, mostly cholesterol stones, affect some 15% of the population. Oral bile salts dissolve human cholesterol gallstones, but with low efficacy, and surgery remains the main therapeutic option. Fatty acid bile acid conjugates (FABACs) were shown to prevent formation of cholesterol gallstones in experimental animals. The aim of this study was to test whether these compounds could dissolve preexisting cholesterol gallstones via oral administration. Inbred, gallstone-susceptible C57J/L mice were given a lithogenic diet for 2 months, and the presence of gallstones was ascertained. The mice were then switched to a regular diet while part of them were given in addition C20-FABAC, by gavage, at a dose of 0.5 or 3 mg per animal per day. All mice tested had cholesterol gallstones after 2 months on the lithogenic diet. In study I, after 2 months on the regular diet, 3 of 4 (75%) of the controls had gallstones, whereas none of the 6 FABAC-fed animals (3 mg/d) had stones (P =.033). In study II, evaluating 2 FABAC doses, after 2 months on the regular diet, 8 of 8 (100%) of the controls had gallstones, which were found in 2 of 7 (28%) and 1 of 8 (12%) of the mice supplemented with 0.5 mg/d (P =.007) or 3 mg/d (P =.001) FABAC, respectively. On a molar basis, the dose of 0.5 mg FABAC is equivalent to 14 mg/kg/d of a bile acid. In conclusion, FABACs given orally can dissolve preexisting cholesterol gallstones in mice. This was accomplished with a dose of FABAC equivalent to the dose of bile acids used in human gallstone dissolution.


Subject(s)
Bile Acids and Salts/therapeutic use , Cholelithiasis/drug therapy , Cholesterol/metabolism , Fatty Acids/therapeutic use , Administration, Oral , Animals , Bile/chemistry , Bile Acids and Salts/administration & dosage , Fatty Acids/administration & dosage , Lipids/analysis , Male , Mice , Mice, Inbred C57BL , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...